Skip to content

ICG-NIR Guided Lymph Node Dissection in Gastric Cancer

Oncologic Safety of Sentinel Lymph Node-guided Lymph Node Dissection Using ICG-NIR Laparoscopy in Gastric Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04056260
Enrollment
219
Registered
2019-08-14
Start date
2020-03-20
Completion date
2020-12-31
Last updated
2020-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach Neoplasm

Brief summary

As the survival rate of patients with gastric cancer has increased, there has been a growing interest in interventions that improve postoperative quality of life. Therefore minimally invasive surgery or endoscopic resection has been performed much more frequently. However, adequate lymph node dissection is important as well. The aim of the study is to identify the feasibility of indocyanine green - near infra-red (ICG-NIR) guided sentinel lymph node dissection for the treatment of gastric cancer.

Interventions

PROCEDUREICG-NIR guided surgery

ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy

Sponsors

Ho Seok Seo
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* dignosed gastric adenocarcinoma * tumor: size 4cm or smaller * depth of invasion: mucosa, submucosa, proper muscle * candidates of laparoscopic radical gastrectomy * informed consent

Exclusion criteria

* metachronous malignancy * number of tumors: 2 or more * remnant gastric cancer * indication for endoscopic resection * history of chemotherapy or radiation therapy * pregnancy * allergy to ICG * metastatic gastric cancer

Design outcomes

Primary

MeasureTime frameDescription
sensitivity and specificity1 monthsensitivity and specificity of ICG-NIR guided lymph node dissection

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026